This study is looking at whether Metformin, a medication, can help people with Focal Segmental Glomerulosclerosis (FSGS). FSGS is a kidney disease where the filtering units (glomeruli) become scarred, which can lead to kidney failure. Researchers want to see if taking Metformin along with your usual care is better than a placebo (an inactive pill) and usual care. They will measure changes in a specific marker in your urine (NPHS2:Creatinine ratio) after 6 months to see if Metformin helps protect the kidney cells called podocytes. The study aims to enroll 30 participants aged 18 to 80 who have been diagnosed with FSGS through a kidney biopsy. The current status of this study is unclear.

Study design

This is an interventional study planning to enroll 30 participants. Participants will be randomly assigned to receive either Metformin or a placebo, both in addition to their standard medical care.

What's involved

Participants will take daily oral tablets for 6 months. The primary measurement will be taken at 6 months after starting the study treatment.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint is measured at 6 months following randomization, indicating a follow-up period of at least 6 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.